Andrew Althouse on Clinical Trial Design and Remdesivir
![The Accad & Koka Report](https://cdn.mises.org/styles/responsive_4_3_650w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=xcYJg8wj 650w,https://cdn.mises.org/styles/responsive_4_3_870w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=4tA-5gSL 870w,https://cdn.mises.org/styles/responsive_4_3_1090w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=HI4f-Rqa 1090w,https://cdn.mises.org/styles/responsive_4_3_1310w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=gL8uwCsq 1310w,https://cdn.mises.org/styles/responsive_4_3_1530w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=H1UV-41Y 1530w)
Our guest is Andrew Althouse, statistician at the Center for Clinical Trials and Data coordination in Pittsburgh. He holds an undergraduate degree in Statistics and a PhD in Epidemiology from the University of Pittsburgh. His main area of interest is the design of randomized control trials. He discusses adaptive randomized control trials, and dissects the recent news of the positive Remdesivir trial.